Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial.
about
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary studyNuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinomaA multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer.Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsPhase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.Antimetabolite Treatment for Pancreatic Cancer.Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patientsThe role of molecular markers in predicting response to therapy in patients with colorectal cancer.Bcl-2 expression significantly correlates with thymidylate synthase expression in colorectal cancer patients.The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.New antimetabolites in cancer chemotherapy and their clinical impactIntegrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase.Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs.ATM, THMS, and RRM1 protein expression in nasopharyngeal carcinomas treated with curative intent.Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer.Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy.TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer.Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness.
P2860
Q21260394-DB38B094-D679-46FE-B166-F331F33A793EQ28366577-61C877B5-5EAE-4EF4-8A6B-3D75198836F8Q31080865-C38A3194-DF05-4E61-9458-87E1F1B6DC76Q33238496-9DBB0BFF-F425-458B-A0E2-8A008B779D81Q33337970-17ABA88F-0DDB-46BE-ACE3-3A80294A0EBBQ33875909-C2209831-802D-4F68-B157-EF59A3B4BA58Q34008793-0E819496-A50F-4939-B3F4-74DD64E4AC75Q35765841-8E38931B-3585-4E79-9DB8-65FBD3185ECEQ35826334-CA3BC2E8-DFC1-490D-BEA2-FDDFE6AB1A34Q36116454-334352E8-1168-4B89-BCF4-2AF58D28DDA6Q36613622-9F56C806-2B49-4D80-AE59-01E540E117F9Q37142001-D7D3C927-9F0F-4A1D-9B09-271101EEBF73Q37386607-2110A86D-41B3-4FBA-A82C-172B26929F6EQ39233316-916950D2-41DB-4070-A908-6FD6048DCA8DQ39702086-8F39692C-62D7-4C3B-8302-556857C82913Q39837916-4A292547-B7BD-430A-B99E-55A704802A11Q40112797-FBE05459-A33A-494D-BE39-386184C4D03CQ40254033-CEE74093-59B9-4B34-B2C7-34B9641DBC7FQ41977175-B80ECE62-7F99-4679-909F-1D399A6C9BF0Q44582607-97175DE9-C6EA-413A-AD98-F1985F093ADEQ45148168-A63C9E6B-3B4A-4D9C-961B-4883D4E91B09Q46187727-9B900D21-A781-4399-B5AD-41096903A476Q46944744-2F50F320-4E60-49DD-B444-6566EC025C4EQ51057342-506D9C3F-FE45-44FC-9844-5F8135F5E86CQ54122487-D7B8180C-FAA8-4DEB-93C2-3FFA83E9C1B2
P2860
Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Quantitation of intratumoral t ...... report from an ongoing trial.
@en
Quantitation of intratumoral t ...... report from an ongoing trial.
@nl
type
label
Quantitation of intratumoral t ...... report from an ongoing trial.
@en
Quantitation of intratumoral t ...... report from an ongoing trial.
@nl
prefLabel
Quantitation of intratumoral t ...... report from an ongoing trial.
@en
Quantitation of intratumoral t ...... report from an ongoing trial.
@nl
P2093
P1476
Quantitation of intratumoral t ...... report from an ongoing trial.
@en
P2093
Danenberg K
Leichman CG
Leichman L
Silberman H
P304
P356
10.1016/0959-8049(95)00326-E
P577
1995-07-01T00:00:00Z